ReviewFrontiers in cell and developmental biology2025
Exosomes and their cargo proteins in diagnosis, process and treatment of gastric cancer.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Exosome-mimetic nanocarriers in cancer diagnosis and drug delivery: engineering strategies, functional biomimicry, safety considerations, and clinical translation.Journal of nanobiotechnology · 2026Review
- Hypericin-loaded small extracellular vesicles increase photodynamic therapy and remodel miRNA-mRNA axes in AGS gastric cancer cells.Scientific reports · 2026Article
- Exosome-orchestrated network in gastric cancer: mechanisms, immune regulation, biomarkers and therapeutic vehicles.Frontiers in cell and developmental biology · 2026Review
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects.Frontiers in immunology · 2026Review
- Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
- PRSS22 promotes the immune evasion of gastric cancer via inhibiting ANXA1-mediated degradation of PD-1.Food & nutrition research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the common malignant tumors of digestive tract. Early diagnosis, process monitoring, and appropriate treatment strategies are crucial to reducing mortality and improving patient outcomes. However, the lack of specific early symptoms and reliable diagnostic markers often leads to delayed diagnosis and suboptimal treatment strategies. Exosomes, as small vesicular structures derived from endosomes, play crucial roles in cell-to-cell communication and have emerged as promising biomarkers and therapeutic targets in various cancers, including gastric cancer. This comprehensive review delves into the significance of exosomes and their cargo proteins, particularly focusing on their applications in the diagnosis, progress and treatment of gastric cancer. Based on this review, we believe that the real-time release characteristics of extracellular vesicle proteins make them an ideal tool for dynamically monitoring gastric cancer progression and treatment response. The potential of extracellular vesicles in "liquid biopsy" can be explored to replace traditional invasive examinations and achieve non-invasive and continuous disease monitoring. In the future, nanotechnology can be combined with artificial intelligence to develop an efficient extracellular vesicle protein capture and analysis platform, in order to enhance diagnostic sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.